Literature DB >> 27935032

Prognostic analysis of patients with epilepsy according to time of relapse after withdrawal of antiepileptic drugs following four seizure-free years.

Soochul Park1, Dong Hyun Lee1, Seung Woo Kim1, Yun Ho Roh2.   

Abstract

OBJECTIVE: We performed a retrospective, prognostic analysis of a cohort of patients with epilepsy according to time of relapse after four seizure-free years.
METHODS: Planned withdrawal of antiepileptic drugs (AEDs) and at least 3 years of follow-up after AED discontinuation were performed. The following two groups were assessed: (1) an early relapse (ER) group of patients who experienced recurrence during AED withdrawal and (2) a late relapse (LR) group of patients who experienced recurrence after completion of the AED discontinuation process. After dichotomization, the relapse rate, prognostic factors, and their impacts for each group were compared with those of a group of patients who continued to be seizure-free after AED withdrawal (SF group) using multiple logistic regression analysis. The AED intake mode was also analyzed.
RESULTS: Two hundred seventeen (64.6%) of the 336 total patients experienced relapse. One hundred thirty-nine patients (41.4%) and 78 patients (23.2%) were included in the LR and ER groups, respectively. Symptom duration >120 months showed the strongest negative prognostic impact as demonstrated by the 4.7-fold higher risk of recurrence in the ER group compared with the SF group. Additional factors with a negative prognostic impact included an age at epilepsy onset of ≤20 years and the presence of localization-related epilepsy. No reliable predictor between the SF and LR groups was revealed. After exclusion of the SF group, post hoc analysis according to age at epilepsy onset and symptom duration showed that the above-mentioned negative prognostic factors significantly affected the relapse patterns of the LR and ER groups. SIGNIFICANCE: The results suggest that longer symptom duration, which could be associated with intrinsic reactivation of epilepsy, is the strongest negative prognostic factor for relapse. Relapse after AED withdrawal in prolonged follow-up of seizure-free patients is one aspect of the natural history of epilepsy.
© 2016 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.

Entities:  

Keywords:  Age at epilepsy onset; Early relapse; Late relapse; Natural history of epilepsy; Symptom duration

Mesh:

Substances:

Year:  2016        PMID: 27935032     DOI: 10.1111/epi.13624

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  4 in total

1.  Relative Seizure Relapse Risks Associated with Antiepileptic Drug Withdrawal After Different Seizure-Free Periods in Adults with Focal Epilepsy: A Prospective, Controlled Follow-Up Study.

Authors:  Xinshi Wang; Ruqian He; Rongyuan Zheng; Siqi Ding; Yi Wang; Xueying Li; Yingjie Hua; Qingyi Zeng; Niange Xia; Zhenguo Zhu; Patrick Kwan; Huiqin Xu
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

2.  Comparison of Long-Term Outcomes of Monotherapy and Polytherapy in Seizure-Free Patients With Epilepsy Following Antiseizure Medication Withdrawal.

Authors:  Yuxuan Wang; Li Xia; Rong Li; Yudan Li; Jingyi Li; Qin Zhou; Songqing Pan
Journal:  Front Neurol       Date:  2021-05-24       Impact factor: 4.003

3.  Mobile Software as a Medical Device (SaMD) for the Treatment of Epilepsy: Development of Digital Therapeutics Comprising Behavioral and Music-Based Interventions for Neurological Disorders.

Authors:  Pegah Afra; Carol S Bruggers; Matthew Sweney; Lilly Fagatele; Fareeha Alavi; Michael Greenwald; Merodean Huntsman; Khanhly Nguyen; Jeremiah K Jones; David Shantz; Grzegorz Bulaj
Journal:  Front Hum Neurosci       Date:  2018-05-01       Impact factor: 3.169

4.  Antiepileptic-drug tapering and seizure recurrence: Correlation with serum drug levels and biomarkers in persons with epilepsy.

Authors:  Sudhir C Sarangi; Sachin Kumar; Manjari Tripathi; Thomas Kaleekal; Surender Singh; Yogendra K Gupta
Journal:  Indian J Pharmacol       Date:  2022 Jan-Feb       Impact factor: 2.833

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.